Cerus Q4 net loss narrows to $1.3M; achieves adj. EBITDA breakeven; reiterates FY2024 guidance

CERUS CORP

Q4 net loss attributable to Cerus narrowed to $1.3M ($0.01/share) from $13.6M ($0.08) a year ago.
Q4 total revenue $53.3M (+4% YoY); product revenue $46.8M (+6% YoY), driven by North America platelet growth.
Achieved Q4 adjusted EBITDA breakeven at +$4.7M vs -$3.7M in Q4 2022.
Reiterated FY2024 product revenue guidance of $172-175M; INTERCEPT Fibrinogen Complex expected $8-10M.
Cash and investments $65.9M at Dec 31; net cash used in ops $43.2M for FY2023, up from $25.6M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CERUS CORP reported Fourth Quarter 2023 results: revenue $53,342, net income Net loss attributable to Cerus Corporation for the fourth quarter of 2023 was $1.3 million, EPS $0.01 per basic and diluted share.

Period: Fourth Quarter 2023
Revenue: $53,342
Net income: Net loss attributable to Cerus Corporation for the fourth quarter of 2023 was $1.3 million
EPS: $0.01 per basic and diluted share
Result: reported results

Exact text from the filing

Total Revenue $53,342 $51,321 $2,021 4% $186,797 $188,315 $(1,518) -1%

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CERUS CORP reported Full-Year 2024 results: revenue $172-175 Million. Guidance reaffirmed.

Period: Full-Year 2024
Revenue: $172-175 Million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

The Company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to $175 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CERUS CORP reported Fourth Quarter and Full-Year 2023 results: revenue $53,342, net income Net loss attributable to Cerus Corporation for the fourth quarter of 2023 was $1.3 million, EPS $0.01 per basic and diluted share. Guidance reaffirmed.

Period: Fourth Quarter and Full-Year 2023
Revenue: $53,342
Net income: Net loss attributable to Cerus Corporation for the fourth quarter of 2023 was $1.3 million
EPS: $0.01 per basic and diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

% 2023 2022 $ % Product Revenue $46,768 $44,034 $2,734 6% $156,367 $162,048 $(5,681) -4% Government Contract Revenue 6,574 7,287 (713) -10% 30,430 26,267 4,163 16% Total Revenue $53,342 $51,321 $2,021 4% $186,797 $188,315 $(1,518) -1% • The Company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to $175 million. Included in

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

CERUS CORP filing history →

Source: SEC EDGAR

accession 0000950170-24-025891

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.